The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial. 
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.

Show more
Type
Public
HQ
Alpharetta, US
Founded
1984
Size (employees)
19 (est)
Biota Pharmaceuticals was founded in 1984 and is headquartered in Alpharetta, US
Report incorrect company information

Biota Pharmaceuticals Office Locations

Biota Pharmaceuticals has an office in Alpharetta
Alpharetta, US (HQ)
100 2500 Northwinds Pkwy
Show all (1)
Report incorrect company information

Biota Pharmaceuticals Financials and Metrics

Biota Pharmaceuticals Financials

Biota Pharmaceuticals's revenue was reported to be $9.30 m in FY, 2016 which is a 62.2% decrease from the previous period.
USD

Revenue (Q3, 2017)

4.9 m

Net income (Q3, 2017)

(4.4 m)

EBIT (Q3, 2017)

(3.8 m)

Cash (31-Mar-2017)

11.8 m
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

68.7 m24.6 m9.3 m

Revenue growth, %

(64%)(62%)

Cost of goods sold

51.1 m3.6 m

Gross profit

17.6 m21 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

12.3 m18.5 m29.5 m700 k13.9 m5.9 m1.7 m1.7 m5.3 m100 k3.8 m4.9 m

Cost of goods sold

10.7 m11.4 m19.3 m1.7 m1.6 m300 k

Gross profit

1.6 m7.1 m10.2 m(1 m)12.3 m5.6 m

Gross profit Margin, %

13%38%35%(143%)88%95%
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

81.7 m44.7 m49.7 m

Current Assets

101.1 m70.8 m72.4 m

PP&E

2 m200 k300 k

Total Assets

114 m79.4 m72.7 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

60.8 m51.4 m80.1 m57.7 m63.7 m61.5 m45.3 m39 m30.6 m45.9 m38.1 m11.8 m

Accounts Receivable

12.9 m26.9 m36.5 m10.1 m3.2 m

Current Assets

75 m79.3 m117.5 m76.1 m86.2 m87.4 m61.2 m58.6 m60.5 m62.8 m56.2 m46.4 m

PP&E

3.5 m3.1 m2.8 m1.6 m1.1 m300 k200 k400 k400 k300 k300 k300 k
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(11 m)(19.1 m)(25.4 m)

Depreciation and Amortization

2.4 m1.1 m100 k

Cash From Operating Activities

(3.3 m)(9.6 m)(14.1 m)

Purchases of PP&E

(100 k)(100 k)(200 k)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(3.9 m)(100 k)3.2 m(6.9 m)6.5 m1.2 m(6.6 m)(6.5 m)(5.2 m)(10 m)(9.1 m)(4.4 m)

Accounts Payable

1.4 m1.7 m1 m(2.2 m)1.3 m3.7 m1.6 m3.4 m1.8 m

Cash From Operating Activities

900 k

Cash From Investing Activities

(200 k)
USDY, 2017

Financial Leverage

1.9 x
Show all financial metrics

Biota Pharmaceuticals Operating Metrics

FY, 2016

Marketed Vaccines

2

Phase II Trials Products

4
Show all operating metrics
Report incorrect company information